Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 31.43
- Piotroski Score 7.00
- Grade Buy
- Symbol (KRYS)
- Company Krystal Biotech, Inc.
- Price $171.87
- Changes Percentage (0.59%)
- Change $1.02
- Day Low $170.70
- Day High $172.48
- Year High $219.34
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/04/2024
- Fiscal Year End N/A
- Average Stock Price Target $205.50
- High Stock Price Target $220.00
- Low Stock Price Target $133.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $2.18
- Trailing P/E Ratio 75.42
- Forward P/E Ratio 75.42
- P/E Growth 75.42
- Net Income $10.93 M
Income Statement
Quarterly
Annual
Latest News of KRYS
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Krystal Biotech Inc (KRYS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...
Krystal Biotech Inc (NASDAQ:KRYS) has seen over $250 million in net VYJUVEK revenue since August 2023. The company reported positive revenue growth, strong profitability, and progress in Europe. Howev...
By Yahoo! Finance | 7 hours ago -
Krystal Biotech Clears Technical Benchmark, Hitting 80-Plus RS Rating
Discover top growth stocks using IBD's RS Rating, which measures a stock's price movement compared to others. Aim for an RS Rating over 80 for best results. Check out Krystal Biotech with a 219.34 ent...
By Investor's Business Daily | 1 day ago -
Krysten Sinema taps into her millions in campaign cash for lavish...
Senator Kyrsten Sinema spent over $216,000 on travel expenses in her final months in office, including trips to Japan and France. She also spent $152,000 on security. Sinema, known for her centrist vi...
By New York Post | 2 weeks ago
